Skip to main content
. 2021 Oct 1;13(19):4957. doi: 10.3390/cancers13194957

Figure 7.

Figure 7

N6L combined to mTORi treatment inactivate mTOR pathway by decreasing RPS6 and 4EBP1 phosphorylation. mTOR pathway inhibition was analyzed using Western blotting in mPDAC (A) and PDX_PDAC (B) cells non-treated (NT) or treated with N6L, RAPA, INK128, and AZD2014 alone or in combination (N6L+RAPA, N6L+INK, or N6L+AZD).